Updates in the Management of
Pulmonary Arterial Hypertension (PAH)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in
the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 15, 2017 to January 31, 2018

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Actelion Pharmaceuticals

Though relatively rare – affecting approximately six per one million people – PAH is a very serious, life threatening condition that worsens over time and for which there is no cure. Approximately half of people diagnosed with PAH will not live past five years, while those with untreated PAH have an average survival expectancy of approximately three years following diagnosis – and even with aggressive management, PAH has a 15% annual mortality rate. Associated treatment costs have risen with the expansion of treatment options, ranging from $18,000 to $244,000 annually per patient. Additionally, PAH often leads to the onset of co-morbidities associated with the disease, which not only puts the patient at higher risk but also increases the costs to the healthcare system. Early diagnosis and accurate classification are keys to managing costs, as incorrect classification can lead to inappropriate treatment decisions and unnecessary costs to the health care system. Emerging treatments including prostanoids are changing the way patients are being treated and clinicians need to understand how to apply treatment algorithms accordingly for pharmacologic decisions.

Upon Completion of this activity, participants will be able to:

  • Analyze the latest data on the safety and efficacy of current and emerging treatment strategies for PAH

  • Examine the current and updated guidelines to find the most appropriate diagnostic measures for PAH

  • Discuss clinical advances in new and emerging therapies including data on oral prostanoids

  • Assess effective multidisciplinary treatment strategies to improve outcomes of patients with PAH

  • Identify the challenges and barriers in the detection, diagnosis, adherence and risk assessment of patients with PAH

Faculty: Jeffrey S. Sager, MD, MSc, FACP, FCCP
Director, Cottage Pulmonary Hypertension Center
Santa Barbara Pulmonary Consultants
Pulmonary Diseases and Critical Care Medicine
Adjunct Clinical Assistant Professor of Medicine, USC


Dr. Sager serves on advisory board/panel, as a consultant and on the speakers bureau for Actelion, Bayer, Gilead Sciences, Lung Biotech and United Therapeutics. He also receives research funding from Actelion, Bayer, Lung Biotech and United Therapeutics. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This educational activity is supported by an educational grant from
Actelion Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue